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some substantial beneﬁts for companies involved in new drug devel-
opment, including expedited review by regulatory authorities and
relaxed criteria for reimbursement. How “rare disease” is deﬁned
therefore has major ﬁnancial implications, both for pharmaceutical
companies and for insurers or public drug reimbursement programs.
All existing deﬁnitions are based, somewhat arbitrarily, on disease
incidence or prevalence. Objectives: What is proposed here is a
functional deﬁnition of rare based on an assessment of the feasibility
of measuring the efﬁcacy of a new treatment in conventional random-
ized controlled trials, to inform regulatory authorities and funding
agencies charged with assessing new therapies being considered for
public funding. Methods: It involves a ﬁve-step process, involving
signiﬁcant negotiations between patient advocacy groups, pharma-
ceutical companies, physicians, and public drug reimbursement pro-
grams, designed to establish the feasibility of carrying out aee front matter Copyright & 2014, International S
r Inc.
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@sympatico.ca.
ndence to: Joe T.R. Clarke, 405-1177 Yonge Street,randomized controlled trial with sufﬁcient statistical power to show
a clinically signiﬁcant treatment effect. Results and Conclusions: The
steps are as follows: 1) identiﬁcation of a speciﬁc disease, including
appropriate genetic deﬁnition; 2) identiﬁcation of clinically relevant
outcomes to evaluate efﬁcacy; 3) establishment of the inherent
variability of measurements of clinically relevant outcomes; 4) calcu-
lation of the sample size required to assess the efﬁcacy of a new
treatment with acceptable statistical power; and 5) estimation of the
difﬁculty of recruiting an adequate sample size given the estimated
prevalence or incidence of the disorder in the population and the
inclusion criteria to be used.
Keywords: drug development, orphan drugs, rare disease, drug
reimbursement.
Copyright & 2014, International Society for Pharmacoeconomics and
Outcomes Research (ISPOR). Published by Elsevier Inc.Introduction
Evaluation of new treatments for rare diseases is inherently
difﬁcult [1,2]. In 1983, the United States enacted orphan drug
legislation with the speciﬁc aim to encourage the development of
new therapies for diseases that are so rare that the likelihood of a
pharmaceutical company recovering the costs of research and
development through sales was small [3]. This allowed for
various measures, including research and development grants,
provision of expedited review, and market exclusivity for a period
of 7 years after approval, facilitating the development of new
drugs for the treatment of rare diseases to achieve proﬁtability for
the manufacturer. Through such measures, the goal of proﬁt-
ability for the manufacturer has been reached for some drugs for
rare diseases [4], albeit with signiﬁcant challenges remaining for
the third-party payers who bear the high costs of such drugs
often without adequate information about value for money [5].
Under the provisions of the U.S. Orphan Drug Act, rare wasdeﬁned as a disease affecting fewer than 200,000 Americans.
The rationale for choosing this threshold for deﬁning “rare”
remains uncertain and relates to incentives for development
and not to decisions relating to reimbursement.
Pressure on public payers in particular to provide reimburse-
ment for new, potentially life-saving therapies for rare diseases
in the absence of unambiguous evidence of effectiveness,
coupled with the societal commitment to fairness in decision
making concerning reimbursement, has led to strategies that
target treatment with the greatest potential for beneﬁt for those
potentially with the most to gain [6]. Because drugs for rare
diseases are often extremely expensive, the incremental cost per
outcome achieved, a routine measure for assessing cost-effec-
tiveness, often exceeds thresholds thought to be reasonable for
health care interventions [7,8]. The development of “rare disease”
policies in this context is stimulated by a drive to deal with
problems of reimbursement as the main obstacle to access to
treatment, rather than as a stimulus to industry to develop newociety for Pharmacoeconomics and Outcomes Research (ISPOR).
Toronto, ON, Canada M4T 2Y4.
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eu). Central to the decision making around providing access to
these very expensive therapies was the commitment to some
assurance that the therapies are, in fact, effective. This is
recognized to be difﬁcult for rare diseases, and each jurisdiction
involved in policy development generally based entry into a
special access process on a deﬁnition of rare [9,10].
The rationale for selecting one incidence or prevalence thresh-
old rather than another for deﬁning rarity has never been clearly
provided, and as a result, chosen thresholds appear arbitrary. The
randomized controlled trial (RCT) remains the criterion standard
test of the efﬁcacy of new therapies, provides the basis for cost-
effectiveness analyses, and is necessary for the endorsement of
new therapies in most jurisdictions. Adequate evidence from
RCTs, however, may not be available for truly rare conditions.
Here, we describe a ﬁve-step approach to a more functional
deﬁnition of rare that takes into explicit account the difﬁculty of
conducting an RCT of sufﬁcient power to provide reimbursement
policy decisionmakers with clear evidence of clinical effectiveness.
It anticipates the need for closer collaboration between regulatory
authorities, industry, clinical scientists, and patient advocacy
groups across the globe than has been customary in the past.Proposed Protocol
Step 1. What Counts as a Disease?
Because a disease may be deﬁned at several different levels,
including clinical, genetic, or pathological, the deﬁnition of what
counts as a speciﬁc, rare disease requires critical reﬂection and will
often evolve as new information on etiology and pathophysiology
emerges. For example, breast cancer would not be regarded as a rare
disease by almost any criteria. Genetic subclasses of the disease,
however, have been identiﬁed with dramatically different responses
to anticancer treatment [11]. A rare subtype of the cancer for which a
subtype-speciﬁc treatment was developed would reasonably qualify
as a rare disease even though cancer itself is a common condition.
The practice of subclassifying diseases is well known as a
means of circumventing barriers to, or restrictions on, marketing
of certain drugs by “creating” a “new disease” out of another well-
known diagnostic entity, what some have dubbed “excessive
diagnostic splitting.” In this situation, a deﬁnition as rare may
be sought by the supplier to facilitate approval and reimburse-
ment for a newly developed drug treatment on the basis of
observations of subjects with a speciﬁc, rare variant of a common
disease. The treatment, however, may be equally applicable to
more common variants of the condition that may not be identi-
ﬁed in the brief submitted for regulatory or reimbursement
approval. The problem of classiﬁcation is particularly challenging
in the case of psychiatric conditions [12], and off-label prescrip-
tion of drugs approved for treatment of one diagnostic entity is
often extended to other variants of the disease. Even Mendelian
genetic diseases, which would appear at ﬁrst inspection to be
easy to identify as speciﬁc diseases, often exhibit marked clinical
heterogeneity. For example, the most common clinical variant of
mucopolysaccharidosis, type II (MPS II), Hunter disease, caused
by hemizygosity for mutations of the IDS gene, is a progressive
disorder in which primary involvement of the brain is common
and prominent and death, without speciﬁc treatment, generally
occurs before the age of 15 years. Attenuated forms of the
condition, however, occur in which primary brain involvement
is minimal [13,14]. MPS II might legitimately be considered to be
several diseases, each exceedingly rare by comparison with the
whole group. Although genotype-phenotype correlations are
helpful in general, the predictive value of a speciﬁc mutation
may be poor in individual patients and the capacity to use thisinformation meaningfully still remains under development; the
potential for it to change medicine from a generalized paradigm
to a personalized paradigm should not be underestimated but
has not yet been realized.
The emergence of pharmacological chaperones as potentially
effective treatments for some genetic diseases underscores the
importance of speciﬁc genotypic diagnosis. In this case, only
some of the mutations associated with a particular disease would
be expected to respond to chaperone therapy, namely, those
shown by appropriate in vitro studies to be associated with the
production of an abnormally labile, though catalytically active,
mutant protein [15].
In the application of the framework proposed here, the onus
would be on providing adequate “proof” of the existence of the rare
disease entity on the basis of appropriate condition-speciﬁc cri-
teria, including clinical severity, its incidence or prevalence, and
that the drug under consideration is speciﬁc for that condition.
Step 2. Based on What Is Known about the Natural History of
the Disease, What Clinically Relevant Outcomes Would Likely
Yield Clear Evidence of Drug Efﬁcacy?
Knowledge of the natural history of a disease is central to the
identiﬁcation of clinically relevant outcomes to be used for
evaluation of any therapeutic intervention by means of clinical
trials of a new therapy. It is futile, for example, to mount a
clinical trial to evaluate the impact of a particular intervention on
a manifestation of the disease that affects only a handful of the
patients likely to be enrolled, or contributes little to the overall
morbidity and mortality of the disease. It is also critically
important to enable disease modeling (such as Markov modeling)
to estimate the predicted impact of interventions at various
stages of a disease, and/or the eventual evaluation of whether
the predicted effects were borne out in the real-world setting
after introducing the new treatment [16,17].
This step needs to consider the appropriateness of surrogate
outcomes versus clinically relevant outcomes in the evaluation of
a speciﬁc therapeutic intervention. Surrogates are generally easier
to measure than clinical outcomes, and the impact of therapy on
a surrogate outcome is often demonstrable long before a beneﬁ-
cial clinical outcome can be demonstrated. This has generated
growing interest in the identiﬁcation of surrogates with the
potential to demonstrate biological efﬁcacy. In many instances,
however, the predictive value of a surrogate outcome is uncertain,
and in some cases, surrogates initially thought to be reliable have
been shown over the course of time to be unreliable [18]. It is
important to distinguish between surrogate markers that are
clinical measures of disease progression and those that are
biochemical markers. The former can often be more clearly linked
to the disease course, whereas the latter relies more on an
assessed statistical relationship with clinically relevant outcomes.
Detailed information on the natural history of rare diseases is
often lacking. Indeed, the rarity of diseases in this category is
precisely what makes conﬁdent predictions of meaningful out-
comes, based on extensive experience with the disorders, impos-
sible or extremely difﬁcult. Published series of more than a
handful of cases are generally nonexistent, or at best rare. There
are some noteworthy exceptions: the large-scale industry-spon-
sored study of the natural history of infantile Pompe disease
stands as an exemplary model of such a project. The results were
sufﬁciently robust that the short-term efﬁcacy of enzyme
replacement therapy (ERT) was clearly established without
recourse to an RCT of the treatment [19].
Studies designed to establish the natural history of a rare
disease and the predictive value of any proposed surrogates are
seen to be primarily the responsibility of those seeking identi-
ﬁcation of a particular disease as rare. In most cases, this would
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programs designed to encourage drug development. However,
specialist physicians and patient advocacy groups also play a
role. Patient advocacy groups are viewed in particular to have a
major role to play in this step and are seen as working closely
with physicians to understand the true incidence, the clinical
spectrum, and the natural history of a rare disease. The informa-
tion on natural history obtained by surveys of physicians and
patient advocacy groups will likely be biased toward more
severely affected individuals with the disorder because they are
the most identiﬁable. In fact, screening programs for some rare
diseases carried out after the emergence of a new treatment for a
rare disease and sponsored by the drug manufacturer have
shown that the true prevalence of a disease may be orders of
magnitude greater than previously thought as a result of the
detection of mildly affected variants, which escape diagnosis by
reference to conventional clinical diagnostic criteria. An excellent
example is Fabry disease, a rare X-linked, multisystem, lysosomal
storage disease. The incidence of the disease was generally
considered to be very low, of the order of 1 case per 50,000 male
births [20,21]. Newborn screening programs in Italy and Taiwan
showed, however, that the identiﬁcation of males with mild
variants of the disease increased the overall incidence to 1 per
3100 and 1 per 1250 newborn males, respectively [22,23]. The
clinical relevance of the mildly affected end of the spectrum
remains unknown, but the pressures to provide prophylactic
treatment are immense, often before the effectiveness of early
intervention is clearly established. Thus, the limited clinical
evidence that is available may not be applicable to most of the
patients now identiﬁed with the disease.
Ultimately, the selection of suitable outcomes for any clinical
trial of a novel therapy for a rare disease would require con-
sultation with appropriate specialist physicians armed with as
much information as is available about the natural history of the
disease, including the major systems consistently involved in
most of the patients and the evolution of the complications with
time. This might require a comprehensive, industry-sponsored
survey of a large number of patients similar to that undertaken to
elucidate the natural history of infantile Pompe disease [19].Step 3. What Is the Inherent Variability of the Outcome
Measures to be Used to Evaluate Drug Efﬁcacy?
Having identiﬁed one or more relevant outcomes, on the basis of
a sound understanding of the natural history of a disease and the
relationship between any proposed surrogates and clinically
important outcomes, the next step is to establish the standard
errors for measurements of these outcomes. This is a relatively
straightforward process for well-established outcome measures,
such as pulmonary function tests or measurements of serum
cholesterol levels. It is more difﬁcult for outcomes designed for
the assessment of the effect of an intervention on a speciﬁc
aspect of a rare disease. The measurement of urinary glycolipid
excretion in the evaluation of treatments of Fabry disease is an
example of a highly specialized and speciﬁc surrogate outcome
that involves at least three sources of uncertainty: the variability
of the measurement itself, the daily biological variability within
an individual patient, and the relationship between the surrogate
and clinically relevant outcomes. The ﬁrst two of these sources of
uncertainty are relatively easy to resolve by appropriate prelimi-
nary studies. The relationship with a clinically relevant outcome
is more difﬁcult. In fact, in this speciﬁc instance, the treatment of
Fabry disease by ERT is associated with highly signiﬁcant reduc-
tions in urinary glycolipid excretion and is generally regarded as
clear evidence of a biological effect. The relationship of this
biomarker to clinical outcomes, however, has been challenged[17]. How this should affect decision making is still unknown,
owing to a paucity of information.
Step 4. How Many Patients Would be Needed to Perform a
Clinical Trial of Reasonable Duration Using Relevant Clinical
Outcomes with a Power of 80%?
This step is perhaps the easiest of all. It simply involves a power
analysis based on the inherent variability of outcomes selected
for the evaluation of the efﬁcacy of a particular new therapy,
coupled with a decision regarding the anticipated effect of the
therapy [24,25]. The results of the analysis indicate the number of
patients required for an RCT to establish with acceptable cer-
tainty that an intervention works or does not work. Armed with a
relatively small amount of information on the proposed out-
comes, almost anyone would be able to carry out the required
power analysis in a matter of minutes.
Step 5. Is an RCT Using the Clinically Relevant Outcomes
Identiﬁed Feasible?
The number of patients required to perform an adequately
powered RCT can be estimated from the sample size calculated
in step 4 together with an estimate of the prevalence of the target
disease in a relevant population. Uncertainty about prevalence is
inevitable; however, prevalence is currently the only criterion on
which the deﬁnition of rare is based in most jurisdictions. In the
case of rare diseases, the need for multicenter trials is taken for
granted. As a result, it may not be unreasonable to insist that
RCTs be multinational. For example, this has become the norm
for clinical trials of the treatment of many cancers and cardio-
vascular disease. Such transjurisdictional clinical trials would
require considerable negotiation to ensure the uniform applica-
tion of standards of diagnosis and monitoring.
One approach is to limit the denominator to that population
that might be eligible for reimbursement from a central, public
drug cost reimbursement program. Another would be to use the
combined populations of a subset of all the countries where a
drug manufacturer anticipates seeking regulatory approval to sell
its product. The true incidence of a rare disease is always difﬁcult
to determine: failure to recognize the possibility of a rare disease
resulting in delayed or missed diagnosis, combined with incom-
plete understanding of the clinical spectrum of rare diseases,
routinely results in the underestimation of disease incidence.
One way to decrease the impact of the failure at the outset to take
into account the existence of a potentially large population of
patients, which includes mild variants escaping recognition,
would be to base the deﬁnition of rare on the clinical severity
of a disease classiﬁed diagnostically according to a generally
accepted biochemical or genetic marker rather than on the
biochemical or molecular marker alone. For example, by focusing
on patients with Gaucher disease or Fabry disease demonstrated
in clinical trials to beneﬁt most from ERT, reimbursement of
patients has been based on the severity of end-organ damage [26–28].
Accordingly, a large number of asymptomatic or minimally
symptomatic patients would not be eligible for reimbursement
unless earlier intervention has been demonstrated clearly to lead
to a signiﬁcantly greater long-term beneﬁt than later interven-
tion. This approach has worked well in the case of Gaucher
disease because, except in the presence of advanced skeletal
complications, the response to ERT is almost always brisk [29]. In
Canada, therefore, symptomatic or minimally symptomatic
patients are treated differently than symptomatic patients. Anal-
ysis of over 6 years of experience with a nationwide study of
virtually all individuals in Canada affected with Fabry disease has
shown that despite a rigorous application of this approach the
outcome of ERT of patients with Fabry disease in this country was
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biochemical or genetic diagnosis alone [28].
Estimation of the number of patients available for enrollment
in any RCT needs to also take into consideration the proportion
that would be considered eligible for enrollment. This is likely to
vary according to the ages, geographic distribution, and inclusion
and exclusion criteria, as well as the anticipated willingness of
patients to participate for whatever reason. This will require
more information about the patient population than would
normally be readily available. It is the sort of information that
is often collected routinely by patient advocacy groups, who have
the potential to play an important role in the process at this
stage, along with appropriate specialist physicians. At present,
however, the involvement of patient advocacy groups has been
limited. What is proposed here is a much larger and earlier
involvement, including active participation, along with specialist
physicians, in the identiﬁcation and recruitment of subjects
suitable for inclusion in clinical trials.
This step requires a realistic determination of the difﬁculty of
recruiting an adequate sample size, and the feasibility of retain-
ing the population for an adequate duration to determine the
clinical relevance of the effect of the treatment, on the basis of
types of outcomes that are “feasible” to collect. For example,
neurocognitive decline is difﬁcult to measure but may be evalu-
able in the shorter term, whereas death is readily measurable but
may require several years or decades to ascertain. Similarly,
consideration of feasibility should be based on availability of
concentrated patient populations (i.e., where genetic variants
may have a geographic concentration) versus dispersed patients
(whereby, random mutations are spread worldwide, and not
concentrated within a localized population), wherein the former
may be more accessible to delivery of clinical care and follow-up
for clinical outcomes, whereas the latter are spread across
various geographic areas and countries, and across a multitude
of health systems and health providers difﬁcult and expensive to
connect, such as through a global RCT.Discussion
The approach suggested here derives from a functional deﬁnition
of rare based on the practicality of undertaking an appropriately
designed RCT (or series of RCTs) with sufﬁcient power to
establish with conﬁdence whether a drug or treatment is effec-
tive. The framework proposes a multiple-stakeholder approach,
and would be best applied “upstream” in the drug development
process so that expected evidence requirements can be “a priori”
deﬁned. This may improve efﬁciencies of drug development and
will allow for a two-way iterative process to deﬁne evidence
expectations as the development proceeds. It would also be
amenable to enhancing “coverage with evidence development”
reimbursement policies, whereby evidence expectations could be
deﬁned early in the process, and with collaborative investigation
of which patient groups have met “adequate” levels of evidence
for conditional reimbursement. For example, this framework
could signiﬁcantly enhance the New Drug Development Para-
digms approach adopted by the European Medicines Agency and
Singapore Health Sciences Authority, taking a proactive, strategic
design of policy with broad stakeholder input, followed by the
empiric evaluation of these designs to inform iterative discussion
to support adaptive licensing [30,31]. With the proposed protocol,
the most straightforward component is the power analysis,
especially when it makes use of the known inherent variability
of well-established and appropriate clinical outcomes to establish
the required sample size. It also, however, involves uncertainties,
some of which are inherent, such as the typical natural history
and the true prevalence of a disease.Dealing with the uncertainties should be regarded as a
collaborative undertaking involving the principal stakeholders:
government regulatory authorities, private or public reimburse-
ment agencies, drug manufacturers, physicians, and patient
advocacy groups. The proposed process implies considerable
early consultation among the various stakeholders, especially
between government regulatory authorities, including those
involved with reimbursement from public funds, and manufac-
turers. Because of the importance of establishing the true prev-
alence, the clinical spectrum, and natural history of a condition,
the negotiations should also include patient advocacy groups and
appropriate specialty physicians. Overall coordination of the
negotiations is seen as primarily the responsibility of government
regulatory authorities, particularly in those situations in which
the payer is another government agency.
The success of the proposed process hinges on the willingness
of the stakeholders to engage in meaningful negotiations. In this
regard, regulatory authorities have a decided advantage, for it is
government that ultimately makes the decision regarding when
treatments for a rare disease should be granted relaxed expect-
ations for the burden of proof, and the allowances and provisions
for this designation. What is proposed here represents the
application of a new working framework requiring a rigorous
approach to diagnosis and the speciﬁcity of a proposed treat-
ment. With respect to new drug development, the beneﬁts gained
when a disease is formally accepted to be rare are substantial and
are not likely to represent a signiﬁcant impediment to the
development of novel treatments for rare diseases. It is important
to emphasize that this approach is intended only to target the
deﬁnition of rare; it does not, by itself, provide the basis for
deciding whether the treatment for a particular condition should
be reimbursed. For example, the application of the statistical
power criterion, using a generally accepted conﬁdence level of
80%, may work well for deciding whether a condition is rare. If
the number of patients with a particularly rare disease is so
small that achievement of this level of statistical power is
virtually impossible, then some other level of statistical power,
or a different study design (such as observational studies),
might be accepted as the “best possible evidence” of efﬁcacy
when it came to deciding whether to reimburse and under what
other conditions. It is worth noting that the decision concerning
the deﬁnition of “best feasible evidence” required for drugs for
rare diseases as applied here is necessary, but not sufﬁcient, for
the decision to reimburse. Local considerations of competing
priorities for limited resources and local sociopolitical consid-
erations related to providing socially acceptable concessions
will inevitably play a role in the ultimate decision. What these
conditions might be is beyond the scope of this article and
would necessarily involve close consultation with regulatory
authorities.
In summary, this framework proposes a functional deﬁnition
of best feasible evidence expectations for treatments for diseases
that goes beyond the deﬁnition of incidence or prevalence alone
for rare diseases based on the practicality of undertaking an
appropriately designed RCT. Such a framework, if applied
upstream during drug development and with transparency
and collaboration with multiple stakeholders, could improve
decision-making processes for regulators and reimbursement
agencies and would better inform innovative development and
reimbursement processes such as adaptive licensing and cov-
erage with evidence development. This approach could
advance the current paradigm, which typically defaults to
suggesting that evidence is “impossible” to achieve for rare
diseases, when, in fact, there are different underlying realities
relating to best feasible level of evidence, and these should be
reﬂected in the development and reimbursement decision-
making process.
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